Pencil Banner Copy AUGUST2023

Elevar Therapeutics and Jiangsu Hengrui Pharma announce global commercialization licensing agreement for camrelizumab LEARN MORE HERE
Title Image

AACR 2023

AACR 2023: Comparative Biochemical Kinase Activity Analysis Identifies Rivoceranib as a Highly Selective VEGFR-2 Inhibitor

This poster was presented at the 2023 AACR Annual Meeting.

To read the full study report download the poster.